• Overview
  • Eligibility
  • More info
  • Locations

Donor Lymphocyte Infusion (DLI) as Adoptive Immunotherapy for Relapse Malignancies After Allogeneic Hematopoietic Transplantation (NCT00003887)

National Cancer Institute (NCI)
RATIONALE: White blood cells from donors may be able to kill cancer cells in patients with cancer that has recurred following bone marrow or peripheral stem cell transplantation. PURPOSE: Phase II trial to study the effectiveness of donated white blood cells in treating patients who have relapsed cancer following transplantation of donated bone marrow or peripheral stem cells.
  • Biological: peripheral blood lymphocyte therapy
    Ages eligible for Study
    1 Years to 70 Years
    Genders eligible for Study
    All
    Accepts Healthy Volunteers
    No
    OBJECTIVES: I. Offer donor lymphocyte infusion as adoptive immunotherapy in patients with relapsed malignancies after allogeneic bone marrow or peripheral blood stem cell transplantation and who are not eligible for other FHCRC protocols.

    OUTLINE: Patients with rapidly progressive disease receive reinduction chemotherapy and radiotherapy prior to study therapy. Donor lymphocyte infusions (DLI) begin after recovery from chemotherapy or sooner, if clinically indicated. Patients receive 1 or more DLI from the original donor. Patients are followed monthly for 3 months, then every 3-6 months for 9 months.

    PROJECTED ACCRUAL: An unlimited number of patients will be accrued for this study.

    1 locations

    United States (1)
    • Fred Hutchinson Cancer Research Center
      Not specified
      Seattle, Washington, United States, 98109
    Status:
    completed
    Type:
    Interventional
    Phase:
    Start:
    31 July, 1998
    Updated:
    27 November, 2011
    Participants:
    0
    A girl giving information about available additional trials.

    FindMeCure helps you find, understand and join clinical trials from all over the world.

    There are more clinical trials for your condition!